Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02962167 · ClinicalTrials.gov registry record · Phase 1

Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

A Phase 1 study of Atypical Teratoid/Rhabdoid Tumor and Medulloblastoma Recurrent, sponsored by Sabine Mueller, MD, PhD.

Completed
Registry status
Phase 1
Development phase
34
Enrollment target
8
Study locations

NCT02962167 is a Phase 1 study of Atypical Teratoid/Rhabdoid Tumor and Medulloblastoma Recurrent that has completed, run by Sabine Mueller, MD, PhD. The registered enrollment target is 34 participants, below the 84-participant average among 7 other Atypical Teratoid/Rhabdoid Tumor trials with a reported enrollment target (60% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02962167, a Phase 1 study of Atypical Teratoid/Rhabdoid Tumor and Medulloblastoma Recurrent, has completed, sponsored by Sabine Mueller, MD, PhD.

COMPLETED
Registry status
Phase 1
Development phase
34 participants
Enrollment target
8
Study locations

Study Summary

This is a three arm Phase I study within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). This study will look to determine the safety and recommended phase 2 dose of the modified measles virus (MV-NIS) in children and young adults with recurrent medulloblastoma or atypical teratoid rhabdoid tumor (ATRT).

Conditions Studied

Atypical Teratoid/Rhabdoid Tumor Medulloblastoma Recurrent Medulloblastoma, Childhood, Recurrent

Interventions

  • BIOLOGICAL Modified Measles Virus
  • BIOLOGICAL Modified Measles Virus Lumbar Puncture

Study Locations (8)

California

  • Children's Hospital Los Angeles - Los Angeles
  • University of California, San Francisco - San Francisco

Illinois

  • Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago

Missouri

  • Washington University in St. Louis - St Louis

Ohio

  • Nationwide Children's Hospital - Columbus

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Utah

  • University of Utah - Salt Lake City

Washington

  • Seattle Children's Hospital - Seattle

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2017-02-22
Est. Completion 2023-05-10
Phase Phase 1

Sponsor

Sabine Mueller, MD, PhD

12 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02962167

The ClinicalTrials.gov registry entry for NCT02962167 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 84-participant average among 7 other Atypical Teratoid/Rhabdoid Tumor trials with a reported enrollment target (60% lower). The listed sponsor is Sabine Mueller, MD, PhD, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Atypical Teratoid/Rhabdoid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Modified Measles Virus is the first listed.

NCT02962167 reports 8 study locations spanning 7 distinct geographic areas - top geographies include California, Illinois, Missouri.

Frequently Asked Questions

What is clinical trial NCT02962167 about?

NCT02962167 is a clinical study titled "Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT". This is a three arm Phase I study within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). This study will look to determine the safety and recommended phase 2 dose of the modified measles virus (MV-NIS) in children and young adults with recurrent medulloblastoma or atypical teratoid rhabdoid...

What is the current status of trial NCT02962167?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2017-02-22. Estimated completion is 2023-05-10.

What conditions does trial NCT02962167 study?

This clinical trial studies the following conditions: Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma Recurrent, Medulloblastoma, Childhood, Recurrent.

What interventions are being tested in trial NCT02962167?

The interventions under investigation include: Modified Measles Virus (BIOLOGICAL), Modified Measles Virus Lumbar Puncture (BIOLOGICAL).

Who is sponsoring clinical trial NCT02962167?

This trial is sponsored by Sabine Mueller, MD, PhD, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02962167 being conducted?

This trial has 8 study locations across California, Illinois, Missouri, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atypical Teratoid/Rhabdoid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atypical Teratoid/Rhabdoid Tumor

All registered trials for this condition

Medulloblastoma Recurrent

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.